Ascendis Net Debt from 2010 to 2026
| ASND Stock | USD 239.22 2.87 1.19% |
Net Debt | First Reported 2013-03-31 | Previous Quarter 274.6 M | Current Value 255.6 M | Quarterly Volatility 295.2 M |
Check Ascendis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascendis Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.8 M, Interest Expense of 81.3 M or Selling General Administrative of 470.4 M, as well as many indicators such as Price To Sales Ratio of 15.11, Dividend Yield of 0.0 or Days Sales Outstanding of 48.19. Ascendis financial statements analysis is a perfect complement when working with Ascendis Pharma Valuation or Volatility modules.
Ascendis | Net Debt | Build AI portfolio with Ascendis Stock |
Analyzing Ascendis Pharma's Net Debt over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Debt has evolved provides context for assessing Ascendis Pharma's current valuation and future prospects.
Latest Ascendis Pharma's Net Debt Growth Pattern
Below is the plot of the Net Debt of Ascendis Pharma AS over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Ascendis Pharma's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ascendis Pharma's overall financial position and show how it may be relating to other accounts over time.
| Net Debt | 10 Years Trend |
|
Net Debt |
| Timeline |
Ascendis Net Debt Regression Statistics
| Arithmetic Mean | (49,013,474) | |
| Geometric Mean | 122,350,702 | |
| Coefficient Of Variation | (539.15) | |
| Mean Deviation | 202,544,025 | |
| Median | (19,430,000) | |
| Standard Deviation | 264,255,105 | |
| Sample Variance | 69830.8T | |
| Range | 912.4M | |
| R-Value | 0.35 | |
| Mean Square Error | 65448.1T | |
| R-Squared | 0.12 | |
| Significance | 0.17 | |
| Slope | 18,228,575 | |
| Total Sum of Squares | 1117292.2T |
Ascendis Net Debt History
Other Fundumenentals of Ascendis Pharma AS
Ascendis Pharma Net Debt component correlations
Click cells to compare fundamentals
About Ascendis Pharma Financial Statements
Ascendis Pharma stakeholders use historical fundamental indicators, such as Ascendis Pharma's Net Debt, to determine how well the company is positioned to perform in the future. Although Ascendis Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascendis Pharma's assets and liabilities are reflected in the revenues and expenses on Ascendis Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascendis Pharma AS. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt | 255.6 M | 268.4 M | |
| Net Debt To EBITDA | (2.24) | (2.13) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out the analysis of Ascendis Pharma Correlation against competitors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Ascendis diversify its offerings? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ascendis Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.43) | Revenue Per Share | Quarterly Revenue Growth 0.423 | Return On Assets | Return On Equity |
Understanding Ascendis Pharma AS requires distinguishing between market price and book value, where the latter reflects Ascendis's accounting equity. The concept of intrinsic value - what Ascendis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ascendis Pharma's price substantially above or below its fundamental value.
Understanding that Ascendis Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascendis Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ascendis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.